Miles P. Mannas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miles P. Mannas has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Derek Jones
Department of Pathology, NYU Langone Health, New York, New York
4 shared publicationsDaniel A. Orringer
NYU Langone Hlth, Dept Neurosurg, New York, NY USA
3 shared publicationsSamir S. Taneja
NYU Langone Hlth, Dept Urol, New York, NY 10016 USA
3 shared publications- Samir S. Taneja
NYU Langone Health
3 shared publications - Adrian Ion-Margineanu
Invenio Imaging
2 shared publications Christian Freudiger
Invenio Imaging, Santa Clara, California
2 shared publications
Latest Publications
- Open Access
- 20 June 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (9) , 223-232
Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models
- 20 June 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (9) , 223-232
Open AccessAutomating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models
- 10 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e68083
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, making early detection and advancements in precision medicine crucial for effective intervention and treatment. A standardized protocol is presented for utilizing stimulated Raman histology (SRH) with integrated artificial intelligence (AI) in prostate cancer detection, offering significant advancements over conventional histopathological methods. SRH provides these advancements by enhancing efficiency through near-real-time, label-free imaging of fresh, unstained tissues, thereby eliminating the delays associated with traditional biopsy analysis. By using stimulated Raman scattering (SRS) microscopy to detect the specific vibrational frequencies of CH2 bonds associated with lipids and CH3 bonds linked to proteins and DNA, cancerous and benign tissues in prostate biopsies can be differentiated. The AI model further enhances diagnostic precision, achieving 98.6% accuracy in identifying prostate cancer. The protocol outlines essential steps for sample preparation, imaging, and data analysis, facilitating improved biobanking processes and enabling downstream applications, such as transcriptomics and xenograft studies. This approach accelerates the diagnostic workflow and shows promise for intraoperative applications, potentially aiding surgeons in identifying positive margins intraoperatively. Additionally, the ability to re-scan and adjust cancer-to-tissue ratios allows for a more tailored analysis of biopsy samples, enhancing tumor detection in unprocessed tissues. Further research and validation are necessary for the widespread adoption of SRH in clinical practice.
- 10 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e68083
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, making early detection and advancements in precision medicine crucial for effective intervention and treatment. A standardized protocol is presented for utilizing stimulated Raman histology (SRH) with integrated artificial intelligence (AI) in prostate cancer detection, offering significant advancements over conventional histopathological methods. SRH provides these advancements by enhancing efficiency through near-real-time, label-free imaging of fresh, unstained tissues, thereby eliminating the delays associated with traditional biopsy analysis. By using stimulated Raman scattering (SRS) microscopy to detect the specific vibrational frequencies of CH2 bonds associated with lipids and CH3 bonds linked to proteins and DNA, cancerous and benign tissues in prostate biopsies can be differentiated. The AI model further enhances diagnostic precision, achieving 98.6% accuracy in identifying prostate cancer. The protocol outlines essential steps for sample preparation, imaging, and data analysis, facilitating improved biobanking processes and enabling downstream applications, such as transcriptomics and xenograft studies. This approach accelerates the diagnostic workflow and shows promise for intraoperative applications, potentially aiding surgeons in identifying positive margins intraoperatively. Additionally, the ability to re-scan and adjust cancer-to-tissue ratios allows for a more tailored analysis of biopsy samples, enhancing tumor detection in unprocessed tissues. Further research and validation are necessary for the widespread adoption of SRH in clinical practice.
- 10 June 2025
- Published by MyJove Corporation
- No. 220,p. e68083
JoVE Video Dataset
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, making early detection and advancements in precision medicine crucial for effective intervention and treatment. A standardized protocol is presented for utilizing stimulated Raman histology (SRH) with integrated artificial intelligence (AI) in prostate cancer detection, offering significant advancements over conventional histopathological methods. SRH provides these advancements by enhancing efficiency through near-real-time, label-free imaging of fresh, unstained tissues, thereby eliminating the delays associated with traditional biopsy analysis. By using stimulated Raman scattering (SRS) microscopy to detect the specific vibrational frequencies of CH2 bonds associated with lipids and CH3 bonds linked to proteins and DNA, cancerous and benign tissues in prostate biopsies can be differentiated. The AI model further enhances diagnostic precision, achieving 98.6% accuracy in identifying prostate cancer. The protocol outlines essential steps for sample preparation, imaging, and data analysis, facilitating improved biobanking processes and enabling downstream applications, such as transcriptomics and xenograft studies. This approach accelerates the diagnostic workflow and shows promise for intraoperative applications, potentially aiding surgeons in identifying positive margins intraoperatively. Additionally, the ability to re-scan and adjust cancer-to-tissue ratios allows for a more tailored analysis of biopsy samples, enhancing tumor detection in unprocessed tissues. Further research and validation are necessary for the widespread adoption of SRH in clinical practice.
- 10 June 2025
- Published by MyJove Corporation
- No. 220,p. e68083
JoVE Video Dataset
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, making early detection and advancements in precision medicine crucial for effective intervention and treatment. A standardized protocol is presented for utilizing stimulated Raman histology (SRH) with integrated artificial intelligence (AI) in prostate cancer detection, offering significant advancements over conventional histopathological methods. SRH provides these advancements by enhancing efficiency through near-real-time, label-free imaging of fresh, unstained tissues, thereby eliminating the delays associated with traditional biopsy analysis. By using stimulated Raman scattering (SRS) microscopy to detect the specific vibrational frequencies of CH2 bonds associated with lipids and CH3 bonds linked to proteins and DNA, cancerous and benign tissues in prostate biopsies can be differentiated. The AI model further enhances diagnostic precision, achieving 98.6% accuracy in identifying prostate cancer. The protocol outlines essential steps for sample preparation, imaging, and data analysis, facilitating improved biobanking processes and enabling downstream applications, such as transcriptomics and xenograft studies. This approach accelerates the diagnostic workflow and shows promise for intraoperative applications, potentially aiding surgeons in identifying positive margins intraoperatively. Additionally, the ability to re-scan and adjust cancer-to-tissue ratios allows for a more tailored analysis of biopsy samples, enhancing tumor detection in unprocessed tissues. Further research and validation are necessary for the widespread adoption of SRH in clinical practice.
- 1 May 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (5) , 609-616
Stimulated Raman Histology and Artificial Intelligence Provide Near Real-Time Interpretation of Radical Prostatectomy Surgical Margins
Balancing surgical margins and functional outcomes is crucial during radical prostatectomy for prostate cancer. Stimulated Raman histology (SRH) is a novel, real-time imaging technique that provides histologic images of fresh, unprocessed, and unstained tissue within minutes, which can be interpreted by either humans or artificial intelligence. Twenty-two participants underwent robotic-assisted laparoscopic radical prostatectomy (RALP) with intraoperative SRH surgical bed assessment. Surgeons resected and imaged surgical bed tissue using SRH and adjusted treatment accordingly. An SRH convolutional neural network was developed and tested on 10 consecutive participants. The accuracy, sensitivity, and specificity of the surgical team's interpretation were compared with final histopathologic assessment. A total of 121 SRH periprostatic surgical bed tissue (PSBT) assessments were conducted, an average of 5.5 per participant. The accuracy of the surgical team's SRH interpretation of resected PSBT samples was 98%, with 83% sensitivity and 99% specificity. Intraoperative SRH assessment identified 43% of participants with a pathologic positive surgical margin intraoperatively. PSBT assessment using the convolutional neural network demonstrated no overlap in tumor probability prediction between benign and tumor infiltrated samples, with mean 0.30% (IQR, 0.10%-0.43%) and 26% (IQR, 18%-34%, P < .005), respectively. SRH demonstrates potential as a valuable tool for real-time intraoperative assessment of surgical margins during RALP. This technique may improve nerve-sparing surgery and facilitate decision-making for further resection, reducing the risk of positive surgical margins and minimizing the risk of recurrence. Further studies with larger cohorts and longer follow-up periods are warranted to confirm the benefits of SRH in RALP.
- 1 May 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (5) , 609-616
Stimulated Raman Histology and Artificial Intelligence Provide Near Real-Time Interpretation of Radical Prostatectomy Surgical Margins
Balancing surgical margins and functional outcomes is crucial during radical prostatectomy for prostate cancer. Stimulated Raman histology (SRH) is a novel, real-time imaging technique that provides histologic images of fresh, unprocessed, and unstained tissue within minutes, which can be interpreted by either humans or artificial intelligence. Twenty-two participants underwent robotic-assisted laparoscopic radical prostatectomy (RALP) with intraoperative SRH surgical bed assessment. Surgeons resected and imaged surgical bed tissue using SRH and adjusted treatment accordingly. An SRH convolutional neural network was developed and tested on 10 consecutive participants. The accuracy, sensitivity, and specificity of the surgical team's interpretation were compared with final histopathologic assessment. A total of 121 SRH periprostatic surgical bed tissue (PSBT) assessments were conducted, an average of 5.5 per participant. The accuracy of the surgical team's SRH interpretation of resected PSBT samples was 98%, with 83% sensitivity and 99% specificity. Intraoperative SRH assessment identified 43% of participants with a pathologic positive surgical margin intraoperatively. PSBT assessment using the convolutional neural network demonstrated no overlap in tumor probability prediction between benign and tumor infiltrated samples, with mean 0.30% (IQR, 0.10%-0.43%) and 26% (IQR, 18%-34%, P < .005), respectively. SRH demonstrates potential as a valuable tool for real-time intraoperative assessment of surgical margins during RALP. This technique may improve nerve-sparing surgery and facilitate decision-making for further resection, reducing the risk of positive surgical margins and minimizing the risk of recurrence. Further studies with larger cohorts and longer follow-up periods are warranted to confirm the benefits of SRH in RALP.
- Open Access
- 6 January 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (1) , e475
The significance of isolated de novo red patches in the bladder in patients referred with suspected urinary tract cancer: Results from the IDENTIFY study
Objectives: To assess the contemporary malignancy rate in isolated de novo red patches in the bladder and associated risk factors for better selection of red patch biopsy.Patients: Patients from the IDENTIFY dataset; Patients referred to secondary care with suspected urinary tract cancer and found to have isolated de novo red patches on cystoscopy.Methods: We reported the unadjusted cancer prevalence in isolated de novo red patches that were biopsied; multivariable logistic regression was used to explore cancer‐associated risk factors including age, sex, smoking, type of haematuria, LUTS, UTIs and a suspicious‐looking red patch (as reported by the cystoscopist). Sub‐analysis of these by clinical role and experience was performed.Results: A total of 1110 patients with isolated de novo red patches were included. 41.5% (n = 461) were biopsied, with a malignancy rate of 12.8% (59/461), which was significantly higher in suspicious versus non‐suspicious red patches (19.1% vs. 2.81%, p < 0.01). There was a significant association between bladder cancer and age (OR 1.04, 95% CI 1.01–1.07, p = 0.01), smoking history (OR 2.62, 95% CI 1.09–6.27, p = 0.03) and suspicious‐looking patch (OR 6.50, 95% CI 2.47–17.1, p < 0.01). The majority of malignancies were in over 60‐year‐olds. Malignancy rates in suspicious versus non‐suspicious red patches did not differ significantly between clinical roles or experiences.Limitations included subjectivity in classifying a suspicious patch and selection bias as not all patches were biopsied.Conclusions: Many patients still undergo unnecessary biopsies under general anaesthetic for isolated de novo red patches. Clinicians should consider the patient's age, smoking status and how suspicious‐looking the patch is, before deciding on surveillance versus biopsy to improve cancer diagnostic yield.
- 6 January 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (1) , e475
Open AccessThe significance of isolated de novo red patches in the bladder in patients referred with suspected urinary tract cancer: Results from the IDENTIFY study
Objectives: To assess the contemporary malignancy rate in isolated de novo red patches in the bladder and associated risk factors for better selection of red patch biopsy.Patients: Patients from the IDENTIFY dataset; Patients referred to secondary care with suspected urinary tract cancer and found to have isolated de novo red patches on cystoscopy.Methods: We reported the unadjusted cancer prevalence in isolated de novo red patches that were biopsied; multivariable logistic regression was used to explore cancer‐associated risk factors including age, sex, smoking, type of haematuria, LUTS, UTIs and a suspicious‐looking red patch (as reported by the cystoscopist). Sub‐analysis of these by clinical role and experience was performed.Results: A total of 1110 patients with isolated de novo red patches were included. 41.5% (n = 461) were biopsied, with a malignancy rate of 12.8% (59/461), which was significantly higher in suspicious versus non‐suspicious red patches (19.1% vs. 2.81%, p < 0.01). There was a significant association between bladder cancer and age (OR 1.04, 95% CI 1.01–1.07, p = 0.01), smoking history (OR 2.62, 95% CI 1.09–6.27, p = 0.03) and suspicious‐looking patch (OR 6.50, 95% CI 2.47–17.1, p < 0.01). The majority of malignancies were in over 60‐year‐olds. Malignancy rates in suspicious versus non‐suspicious red patches did not differ significantly between clinical roles or experiences.Limitations included subjectivity in classifying a suspicious patch and selection bias as not all patches were biopsied.Conclusions: Many patients still undergo unnecessary biopsies under general anaesthetic for isolated de novo red patches. Clinicians should consider the patient's age, smoking status and how suspicious‐looking the patch is, before deciding on surveillance versus biopsy to improve cancer diagnostic yield.
- Open Access
- 10 August 2024
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (1) , 64.e19-64.e25
Intraoperative margin assessment with near real time pathology during partial gland ablation of prostate cancer: A feasibility study
- 10 August 2024
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (1) , 64.e19-64.e25
Open AccessIntraoperative margin assessment with near real time pathology during partial gland ablation of prostate cancer: A feasibility study
- 1 March 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 211 (3) , 384-391
Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies
Stimulated Raman histology is an innovative technology that generates real-time, high-resolution microscopic images of unprocessed tissue, significantly reducing prostate biopsy interpretation time. This study aims to evaluate the ability for an artificial intelligence convolutional neural network to interpretate prostate biopsy histologic images created with stimulated Raman histology. Unprocessed, unlabeled prostate biopsies were prospectively imaged using a stimulated Raman histology microscope. Following stimulated Raman histology creation, the cores underwent standard pathological processing and interpretation by at least 2 genitourinary pathologists to establish a ground truth assessment. A network, trained on 303 prostate biopsies from 100 participants, was used to measure the accuracy, sensitivity, and specificity of detecting prostate cancer on stimulated Raman histology relative to conventional pathology. The performance of the artificial intelligence was evaluated on an independent 113-biopsy test set. Prostate biopsy images obtained through stimulated Raman histology can be generated within a time frame of 2 to 2.75 minutes. The artificial intelligence system achieved a rapid classification of prostate biopsies with cancer, with a potential identification time of approximately 1 minute. The artificial intelligence demonstrated an impressive accuracy of 96.5% in detecting prostate cancer. Moreover, the artificial intelligence exhibited a sensitivity of 96.3% and a specificity of 96.6%. Stimulated Raman histology generates microscopic images capable of accurately identifying prostate cancer in real time, without the need for sectioning or tissue processing. These images can be interpreted by artificial intelligence, providing physicians with near-real-time pathological feedback during the diagnosis or treatment of prostate cancer.
- 1 March 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 211 (3) , 384-391
Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies
Stimulated Raman histology is an innovative technology that generates real-time, high-resolution microscopic images of unprocessed tissue, significantly reducing prostate biopsy interpretation time. This study aims to evaluate the ability for an artificial intelligence convolutional neural network to interpretate prostate biopsy histologic images created with stimulated Raman histology. Unprocessed, unlabeled prostate biopsies were prospectively imaged using a stimulated Raman histology microscope. Following stimulated Raman histology creation, the cores underwent standard pathological processing and interpretation by at least 2 genitourinary pathologists to establish a ground truth assessment. A network, trained on 303 prostate biopsies from 100 participants, was used to measure the accuracy, sensitivity, and specificity of detecting prostate cancer on stimulated Raman histology relative to conventional pathology. The performance of the artificial intelligence was evaluated on an independent 113-biopsy test set. Prostate biopsy images obtained through stimulated Raman histology can be generated within a time frame of 2 to 2.75 minutes. The artificial intelligence system achieved a rapid classification of prostate biopsies with cancer, with a potential identification time of approximately 1 minute. The artificial intelligence demonstrated an impressive accuracy of 96.5% in detecting prostate cancer. Moreover, the artificial intelligence exhibited a sensitivity of 96.3% and a specificity of 96.6%. Stimulated Raman histology generates microscopic images capable of accurately identifying prostate cancer in real time, without the need for sectioning or tissue processing. These images can be interpreted by artificial intelligence, providing physicians with near-real-time pathological feedback during the diagnosis or treatment of prostate cancer.
- 23 May 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (7) , 328.e9-328.e13
Stimulated Raman histology as a method to determine the adequacy of renal mass biopsy and identify malignant subtypes of renal cell carcinoma
- 23 May 2023
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (7) , 328.e9-328.e13
Stimulated Raman histology as a method to determine the adequacy of renal mass biopsy and identify malignant subtypes of renal cell carcinoma
- Open Access
- 8 May 2023
- Published by Wiley in The Prostate
- Vol. 83 (11) , 1060-1067
Stimulated Raman histology, a novel method to allow for rapid pathologic examination of unprocessed, fresh prostate biopsies
Introduction: Delay between targeted prostate biopsy (PB) and pathologic diagnosis can lead to a concern of inadequate sampling and repeated biopsy. Stimulated Raman histology (SRH) is a novel microscopic technique allowing real‐time, label‐free, high‐resolution microscopic images of unprocessed, unsectioned tissue. This technology holds potential to decrease the time for PB diagnosis from days to minutes. We evaluated the concordance of pathologist interpretation of PB SRH as compared with traditional hematoxylin and eosin (H&E) stained slides.Methods: Men undergoing prostatectomy were included in an IRB‐approved prospective study. Ex vivo 18‐gauge PB cores, taken from prostatectomy specimen, were scanned in an SRH microscope (NIO; Invenio Imaging) at 20 microns depth using two Raman shifts: 2845 and 2930 cm−1, to create SRH images. The cores were then processed as per normal pathologic protocols. Sixteen PB containing a mix of benign and malignant histology were used as an SRH training cohort for four genitourinary pathologists, who were then tested on a set of 32 PBs imaged by SRH and processed by traditional H&E. Sensitivity, specificity, accuracy, and concordance for prostate cancer (PCa) detection on SRH relative to H&E were assessed.Results: The mean pathologist accuracy for the identification of any PCa on PB SRH was 95.7%. In identifying any PCa or ISUP grade group 2–5 PCa, a pathologist was independently able to achieve good and very good concordance (κ: 0.769 and 0.845, respectively; p < 0.001). After individual assessment was completed a pathology consensus conference was held for the interpretation of the PB SRH; after the consensus conference the pathologists' concordance in identifying any PCa was also very good (κ: 0.925, p < 0.001; sensitivity 95.6%; specificity 100%).Conclusion: SRH produces high‐quality microscopic images that allow for accurate identification of PCa in real‐time without need for sectioning or tissue processing. The pathologist performance improved through progressive training, showing that ultimately high accuracy can be obtained. Ongoing SRH evaluation in the diagnostic and treatment setting hold promise to reduce time to tissue diagnosis, while interpretation by convolutional neural network may further improve diagnostic characteristics and broaden use.
- 8 May 2023
- Published by Wiley in The Prostate
- Vol. 83 (11) , 1060-1067
Open AccessStimulated Raman histology, a novel method to allow for rapid pathologic examination of unprocessed, fresh prostate biopsies
Introduction: Delay between targeted prostate biopsy (PB) and pathologic diagnosis can lead to a concern of inadequate sampling and repeated biopsy. Stimulated Raman histology (SRH) is a novel microscopic technique allowing real‐time, label‐free, high‐resolution microscopic images of unprocessed, unsectioned tissue. This technology holds potential to decrease the time for PB diagnosis from days to minutes. We evaluated the concordance of pathologist interpretation of PB SRH as compared with traditional hematoxylin and eosin (H&E) stained slides.Methods: Men undergoing prostatectomy were included in an IRB‐approved prospective study. Ex vivo 18‐gauge PB cores, taken from prostatectomy specimen, were scanned in an SRH microscope (NIO; Invenio Imaging) at 20 microns depth using two Raman shifts: 2845 and 2930 cm−1, to create SRH images. The cores were then processed as per normal pathologic protocols. Sixteen PB containing a mix of benign and malignant histology were used as an SRH training cohort for four genitourinary pathologists, who were then tested on a set of 32 PBs imaged by SRH and processed by traditional H&E. Sensitivity, specificity, accuracy, and concordance for prostate cancer (PCa) detection on SRH relative to H&E were assessed.Results: The mean pathologist accuracy for the identification of any PCa on PB SRH was 95.7%. In identifying any PCa or ISUP grade group 2–5 PCa, a pathologist was independently able to achieve good and very good concordance (κ: 0.769 and 0.845, respectively; p < 0.001). After individual assessment was completed a pathology consensus conference was held for the interpretation of the PB SRH; after the consensus conference the pathologists' concordance in identifying any PCa was also very good (κ: 0.925, p < 0.001; sensitivity 95.6%; specificity 100%).Conclusion: SRH produces high‐quality microscopic images that allow for accurate identification of PCa in real‐time without need for sectioning or tissue processing. The pathologist performance improved through progressive training, showing that ultimately high accuracy can be obtained. Ongoing SRH evaluation in the diagnostic and treatment setting hold promise to reduce time to tissue diagnosis, while interpretation by convolutional neural network may further improve diagnostic characteristics and broaden use.
- Open Access
A Multi-Faceted Approach to Communicate the Risks Associated with E-Cigarette Use to Youth
The use of electronic cigarettes among young people has been increasing in recent years. Electronic cigarettes are marketed in ways that attract young people and downplay the risks of these products. For example, electronic cigarettes are available in a variety of flavours, such as mint or chocolate, and it can be quite challenging for young people to understand the potential harms of these products when they are marketed through enticing advertisements under the veil of harmless flavours. Moreover, recent research has shown that electronic cigarette usage may be disproportionately higher for youth with lower socioeconomic status. It is well documented in the literature that electronic cigarettes can have a multitude of negative health impacts on young people. Electronic cigarette use affects all biopsychosocial domains, including but not limited to cardiovascular disease, pulmonary disease, renal disease, mental health, substance use, and interpersonal relationships. Given the increase in electronic cigarette use and lower levels of understanding of the harms these products can have on health, it is essential to develop additional strategies to ensure that young people are made aware of the risks associated with the use of electronic cigarettes. We propose a five factor model that aims to provide support to policymakers, educators, health care professionals, families, and youth. For policymakers, it is necessary to develop policies that limit the access the youth have to electronic cigarettes. In educational settings, educators can incorporate education on electronic cigarettes in the classroom. Health care professionals should have access to tools to ensure they feel comfortable discussing the risks of electronic cigarettes with their young patients. Additionally, families should have access to evidence-based information on the risks associated with electronic cigarettes and on how to communicate with their children about electronic cigarettes. Finally, we should aim to directly reach youth and communicate the potential risks of electronic cigarette use through the social media platforms that they frequent. Ultimately, this paper provides a model that can be used by various stakeholders involved in the public health system. Moving forward, implementing and conducting short, intermediate and long-term evaluation of this model can provide insight into its effectiveness in communicating the risks associated with electronic cigarette use for young people.
Open AccessA Multi-Faceted Approach to Communicate the Risks Associated with E-Cigarette Use to Youth
The use of electronic cigarettes among young people has been increasing in recent years. Electronic cigarettes are marketed in ways that attract young people and downplay the risks of these products. For example, electronic cigarettes are available in a variety of flavours, such as mint or chocolate, and it can be quite challenging for young people to understand the potential harms of these products when they are marketed through enticing advertisements under the veil of harmless flavours. Moreover, recent research has shown that electronic cigarette usage may be disproportionately higher for youth with lower socioeconomic status. It is well documented in the literature that electronic cigarettes can have a multitude of negative health impacts on young people. Electronic cigarette use affects all biopsychosocial domains, including but not limited to cardiovascular disease, pulmonary disease, renal disease, mental health, substance use, and interpersonal relationships. Given the increase in electronic cigarette use and lower levels of understanding of the harms these products can have on health, it is essential to develop additional strategies to ensure that young people are made aware of the risks associated with the use of electronic cigarettes. We propose a five factor model that aims to provide support to policymakers, educators, health care professionals, families, and youth. For policymakers, it is necessary to develop policies that limit the access the youth have to electronic cigarettes. In educational settings, educators can incorporate education on electronic cigarettes in the classroom. Health care professionals should have access to tools to ensure they feel comfortable discussing the risks of electronic cigarettes with their young patients. Additionally, families should have access to evidence-based information on the risks associated with electronic cigarettes and on how to communicate with their children about electronic cigarettes. Finally, we should aim to directly reach youth and communicate the potential risks of electronic cigarette use through the social media platforms that they frequent. Ultimately, this paper provides a model that can be used by various stakeholders involved in the public health system. Moving forward, implementing and conducting short, intermediate and long-term evaluation of this model can provide insight into its effectiveness in communicating the risks associated with electronic cigarette use for young people.